1-NA-PP1 - CAS 221243-82-9
Not Intended for Therapeutic Use. For research use only.
Category:
Inhibitor
Product Name:
1-NA-PP1
Catalog Number:
221243-82-9
CAS Number:
221243-82-9
COA:
Inquire
MSDS:
Inquire
Targets:
Src
Chemical Structure
CAS 221243-82-9 1-NA-PP1

Related Src Products


T338C Src-IN-2
(CAS: 1351927-00-8)

T338C Src-IN-2, a pyrazolopyrimidine detivative, has been found to be a c-Src T338C kinase inhibitor and could be significant for determing the effect of kinase...

CAS 837422-57-8 WH-4-023

WH-4-023
(CAS: 837422-57-8)

WH-4-023 is a potent and selective dual Lck/Src inhibitor with IC50 of 2 nM/6 nM for Lck and Src kinase respectively. The lymphocyte-specific kinase (Lck) is a ...

eCF506
(CAS: 1914078-41-3)

eCF506 is a potent and highl selective inhibitor towards Src tyrosine kinase with a 1000-fold selectivity over ABL. eCF506 inhibits SRC at subnanomolar concentr...

CAS 172889-27-9 PP2

PP2
(CAS: 172889-27-9)

MCB-613
(CAS: 1162656-22-5)

MCB-613 is a potent steroid receptor coactivator (SRC) stimulator.

CAS 172889-26-8 PP1

PP1
(CAS: 172889-26-8)

CAS 867334-05-2 TG 100572

TG 100572
(CAS: 867334-05-2)

TG 100572 is a multi-targeted kinase inhibitor that inhibits select growth factor receptor tyrosine kinases and Src familt kinases.

CAS 364042-47-7 A 419259

A 419259
(CAS: 364042-47-7)

A-419259 is a potent inhibitor of Src family kinases. IC50 values for src, lck, blk, csk, fyn and lyn range between 15 and 50 nM.

CHMFL-ABL-053
(CAS: 1808287-83-3)

CHMFL-ABL-053 is a potent and orally available inhibitor of BCR-ABL (IC50 = 70nM) without inhibitory activity against c-KIT kinase that is a common target of BC...

CAS 1038395-65-1 KX2-391 dihydrochloride

KX2-391 dihydrochloride
(CAS: 1038395-65-1)

KX2-391 2Hcl is the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell line...

CAS 529-53-3 Scutellartln

Scutellartln
(CAS: 529-53-3)

Scutellarein is a flavonoid isolated from Scutellaria lateriflora could improve neuronal injury.

WEHI-345 analogue
(CAS: 1354825-62-9)

An analogue of WEHI-345, a pyrazolo-pyridine derivative, is a protein kinase inhibitor and could be significant for studying the mechanism of cancer.

CAS 221243-82-9 1-NA-PP1

1-NA-PP1
(CAS: 221243-82-9)

AP-22161
(CAS: 268741-42-0)

AP-2216, designed to bind selectively to the Src SH2 domain by targeting a cysteine residue, has the potential to be further developed for treating osteoporosis...

AP-22408
(CAS: 268741-43-1)

AP-22408, a Src tyrosine kinase inhibitor, is an orally bioavailable phosphotyrosine mimic resulting from a structurebased design.

CAS 330161-87-0 SU6656

SU6656
(CAS: 330161-87-0)

SU6656 is a Src family kinase inhibitor developed by the biotechnology company SUGEN Inc (a subsidiary of Pharmacia) in 2000. SU6656 was initially identified as...

CAS 380843-75-4 Bosutinib

Bosutinib
(CAS: 380843-75-4)

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM, respectively.

CAS 869748-10-7 A-770041

A-770041
(CAS: 869748-10-7)

A-770041 is an selective and orally bioavailable pyrazolo[3,4-d]pyrimidine exhibiting selectivity for Lck compared with previously reported compounds. It is 300...

T338C Src-IN-1
(CAS: 1351926-90-3)

T338C Src-IN-1, a pyrazolopyrimidine detivative, has been found effective T338C inhibition and could be significant for determing the effect of kinases by Chemi...

HG-9-91-01
(CAS: 1456858-58-4)

HG-9-91-01,a small molecule inhibitor that targets specificly salt-inducible kinase (SIKs) IC50: SIK1=0.92 nM; SIK2=6.6 nM; SIK3=9.6 nM

Reference Reading


1.New pyrazolopyrimidine inhibitors of protein kinase d as potent anticancer agents for prostate cancer cells.
Tandon M1, Johnson J, Li Z, Xu S, Wipf P, Wang QJ. PLoS One. 2013 Sep 23;8(9):e75601. doi: 10.1371/journal.pone.0075601. eCollection 2013.
The emergence of protein kinase D (PKD) as a potential therapeutic target for several diseases including cancer has triggered the search for potent, selective, and cell-permeable small molecule inhibitors. In this study, we describe the identification, in vitro characterization, structure-activity analysis, and biological evaluation of a novel PKD inhibitory scaffold exemplified by 1-naphthyl PP1 (1-NA-PP1). 1-NA-PP1 and IKK-16 were identified as pan-PKD inhibitors in a small-scale targeted kinase inhibitor library assay. Both screening hits inhibited PKD isoforms at about 100 nM and were ATP-competitive inhibitors. Analysis of several related kinases indicated that 1-NA-PP1 was highly selective for PKD as compared to IKK-16. SAR analysis showed that 1-NA-PP1 was considerably more potent and showed distinct substituent effects at the pyrazolopyrimidine core. 1-NA-PP1 was cell-active, and potently blocked prostate cancer cell proliferation by inducing G2/M arrest.
2.A chemical-genetic approach to elucidate protein kinase function in planta.
Böhmer M1, Romeis T. Plant Mol Biol. 2007 Dec;65(6):817-27. Epub 2007 Oct 9.
The major objective in protein kinase research is the identification of the biological process, in which an individual enzyme is integrated. Protein kinase-mediated signalling is thereby often addressed by single knock-out mutation- or co-suppression-based reverse genetics approaches. If a protein kinase of interest is a member of a multi gene family, however, no obvious phenotypic alteration in the morphology or in biochemical parameters may become evident because mutant phenotypes may be compensated by functional redundancy or homeostasis. Here we establish a chemical-genetic screen combining ATP-analogue sensitive (as) kinase variants and molecular fingerprinting techniques to study members of the plant calcium-dependent protein kinase (CDPK) family in vivo. CDPKs have been implicated in fast signalling responses upon external abiotic and biotic stress stimuli. CDPKs carrying the as-mutation did not show altered phosphorylation kinetics with ATP as substrate, but were able to use ATP analogues as phosphate donors or as kinase inhibitors.
3.Aurora A is involved in central spindle assembly through phosphorylation of Ser 19 in P150Glued.
Reboutier D1, Troadec MB, Cremet JY, Chauvin L, Guen V, Salaun P, Prigent C. J Cell Biol. 2013 Apr 1;201(1):65-79. doi: 10.1083/jcb.201210060.
Knowledge of Aurora A kinase functions is limited to premetaphase events, particularly centrosome maturation, G2/M transition, and mitotic spindle assembly. The involvement of Aurora A in events after metaphase has only been suggested because appropriate experiments are technically difficult. We report here the design of the first human Aurora A kinase (as-AurA) engineered by chemical genetics techniques. This kinase is fully functional biochemically and in cells, and is rapidly and specifically inhibited by the ATP analogue 1-Naphthyl-PP1 (1-Na-PP1). By treating cells exclusively expressing the as-AurA with 1-Na-PP1, we discovered that Aurora A is required for central spindle assembly in anaphase through phosphorylation of Ser 19 of P150Glued. This paper thus describes a new Aurora A function that takes place after the metaphase-to-anaphase transition and a new powerful tool to search for and study new Aurora A functions.
4.Selective chemical genetic inhibition of protein kinase C epsilon reduces ethanol consumption in mice.
Maiya R1, McMahon T2, Wang D2, Kanter B2, Gandhi D1, Chapman HL1, Miller J2, Messing RO3. Neuropharmacology. 2016 Mar 3;107:40-48. doi: 10.1016/j.neuropharm.2016.02.036. [Epub ahead of print]
Reducing expression or inhibiting translocation of protein kinase C epsilon (PKCε) prolongs ethanol intoxication and decreases ethanol consumption in mice. However, we do not know if this phenotype is due to reduced PKCε kinase activity or to impairment of kinase-independent functions. In this study, we used a chemical-genetic strategy to determine whether a potent and highly selective inhibitor of PKCε catalytic activity reduces ethanol consumption. We generated ATP analog-specific PKCε (AS-PKCε) knock-in mice harboring a point mutation in the ATP binding site of PKCε that renders the mutant kinase highly sensitive to inhibition by 1-tert-butyl-3-naphthalen-1-ylpyrazolo[3,4-d]pyrimidin-4-amine (1-NA-PP1). Systemically administered 1-NA-PP1 readily crossed the blood brain barrier and inhibited PKCε-mediated phosphorylation. 1-NA-PP1 reversibly reduced ethanol consumption by AS-PKCε mice but not by wild type mice lacking the AS-PKCε mutation.